

# David F Jarrard

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1650512/david-f-jarrard-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

3,919  
citations

28  
h-index

62  
g-index

86  
ext. papers

4,880  
ext. citations

4.5  
avg, IF

5.11  
L-index

#	Paper	IF	Citations
80	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 737-46	59.2	1460
79	Therapy-induced senescence in cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1536-46	9.7	482
78	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHARTED Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1080-1087	2.2	373
77	The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. <i>Journal of Urology</i> , <b>2007</b> , 177, 822-31	2.5	99
76	The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. <i>Neoplasia</i> , <b>2005</b> , 7, 816-23	6.4	92
75	Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. <i>Oncogene</i> , <b>2001</b> , 20, 8184-92	9.2	86
74	Modulation of CXCL14 (BRAK) expression in prostate cancer. <i>Prostate</i> , <b>2005</b> , 64, 67-74	4.2	85
73	Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. <i>Cancer Research</i> , <b>2008</b> , 68, 6797-802	10.1	68
72	Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. <i>Cancer</i> , <b>2013</b> , 119, 3992-4002	6.4	58
71	Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality?. <i>European Urology</i> , <b>2014</b> , 66, 1139-47	10.2	53
70	Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. <i>Prostate</i> , <b>2011</b> , 71, 1621-30	4.2	50
69	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1088-1095	2.2	45
68	Epigenetic susceptibility factors for prostate cancer with aging. <i>Prostate</i> , <b>2013</b> , 73, 1721-30	4.2	40
67	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 376-382	2.2	40
66	Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. <i>Neoplasia</i> , <b>2013</b> , 15, 399-408	6.4	39
65	Superoxide dismutase 1 knockdown induces oxidative stress and DNA methylation loss in the prostate. <i>Epigenetics</i> , <b>2010</b> , 5, 402-9	5.7	38
64	HP1 expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. <i>BMC Cancer</i> , <b>2013</b> , 13, 148	4.8	36

63	Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo. <i>Prostate</i> , <b>2013</b> , 73, 337-45	4.2	36
62	A high-throughput method to identify novel senescence-inducing compounds. <i>Journal of Biomolecular Screening</i> , <b>2009</b> , 14, 853-8		35
61	Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. <i>Journal of Urology</i> , <b>2015</b> , 194, 886-91	2.5	33
60	A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 52218-26	5.4	33
59	Overexpression of the novel senescence marker $\beta$ -galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124366	3.7	33
58	Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. <i>Journal of Urology</i> , <b>2018</b> , 200, 1256-1263	2.5	32
57	Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?. <i>Urologic Clinics of North America</i> , <b>2017</b> , 44, 611-621	2.9	31
56	Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. <i>Developmental Biology</i> , <b>2014</b> , 396, 237-45	3.1	31
55	Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2009</b> , 17, 23-30	1.9	31
54	Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. <i>BMC Cancer</i> , <b>2017</b> , 17, 874	4.8	30
53	Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. <i>Journal of Urology</i> , <b>2013</b> , 189, 2335-41	2.5	28
52	A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-B activation. <i>PLoS ONE</i> , <b>2014</b> , 9, e88052	3.7	23
51	The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. <i>Current Opinion in Urology</i> , <b>2015</b> , 25, 83-8	2.8	22
50	CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. <i>Journal of Urology</i> , <b>2013</b> , 189, 329-35	2.5	22
49	Does zinc supplementation increase the risk of prostate cancer?. <i>JAMA Ophthalmology</i> , <b>2005</b> , 123, 102-3		21
48	Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer. <i>Neoplasia</i> , <b>2014</b> , 16, 1018-27	6.4	20
47	Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. <i>Journal of Urology</i> , <b>2019</b> , 201, 876-885	2.5	20
46	Loss of Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth. <i>Cancer Research</i> , <b>2017</b> , 77, 5236-5247	10.1	19

45	Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. <i>ACS Chemical Biology</i> , <b>2017</b> , 12, 2804-2814	4.9	18
44	Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 739-43	2.8	18
43	Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , <b>2014</b> , 18, 282-7	2.2	18
42	The impact of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: A large observational study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 130-137	2.8	18
41	Addressing the need for repeat prostate biopsy: new technology and approaches. <i>Nature Reviews Urology</i> , <b>2015</b> , 12, 435-44	5.5	17
40	Decreased <i>skp2</i> expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. <i>Translational Oncology</i> , <b>2012</b> , 5, 278-87	4.9	16
39	Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172048	3.7	15
38	Inducible expression of cancer-testis antigens in human prostate cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 84359-84374	3.4	14
37	Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , <b>2015</b> , 194, 1214-9	2.5	12
36	CTCF loss mediates unique DNA hypermethylation landscapes in human cancers. <i>Clinical Epigenetics</i> , <b>2020</b> , 12, 80	7.7	11
35	Semen AMACR protein as a novel method for detecting prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 532.e1-532.e7	2.8	11
34	Clinical and pathologic factors predicting reclassification in active surveillance cohorts. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2018</b> , 44, 440-451	2	8
33	Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery. <i>Urology</i> , <b>2020</b> , 135, 88-94	1.6	8
32	Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. <i>Asian Journal of Urology</i> , <b>2019</b> , 6, 57-64	2.7	7
31	Long Noncoding RNAs AC009014.3 and Newly Discovered XPLAID Differentiate Aggressive and Indolent Prostate Cancers. <i>Translational Oncology</i> , <b>2018</b> , 11, 808-814	4.9	5
30	Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. <i>Urology</i> , <b>2017</b> , 100, 139-144	1.6	5
29	Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. <i>American Journal of Clinical and Experimental Urology</i> , <b>2016</b> , 4, 17-27	1.6	5
28	Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2278-2287	6.1	5

27	Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. <i>BJU International</i> , <b>2016</b> , 118, 399-407	5.6	5
26	Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 88.e19-88.e25	2.8	5
25	Reduced estimated glomerular filtration rate (eGFR). <i>BJU International</i> , <b>2017</b> , 120, 387-393	5.6	4
24	Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection. <i>PLoS ONE</i> , <b>2019</b> , 14, e0218950	3.7	4
23	Pyrosequencing for accurate imprinted allele expression analysis. <i>Journal of Cellular Biochemistry</i> , <b>2015</b> , 116, 1165-70	4.7	4
22	Analysis of urological procedures in men who died from prostate cancer using a population-based approach. <i>BJU International</i> , <b>2013</b> , 111, E65-70	5.6	4
21	Pyrosequencing for the rapid and efficient quantification of allele-specific expression. <i>Epigenetics</i> , <b>2013</b> , 8, 1039-42	5.7	4
20	Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. <i>Clinical Epigenetics</i> , <b>2019</b> , 11, 168	7.7	4
19	Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. <i>BioTechniques</i> , <b>2018</b> , 64, 13-19	2.5	4
18	A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. <i>Urology</i> , <b>2016</b> , 96, 93-98	1.6	3
17	Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. <i>Oncogene</i> , <b>2021</b> , 40, 1064-1076.2		3
16	A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. <i>Prostate</i> , <b>2021</b> , 81, 41-49	4.2	3
15	Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients With Advanced Prostate Cancer: A Veterans Administration Cohort Study. <i>Urology</i> , <b>2021</b> , 155, 186-191	1.6	3
14	INDIANA POUCH URINARY DIVERSION FOR ADENOCARCINOMA DEVELOPING AFTER URETEROSIGMOIDOSTOMY. <i>Journal of Urology</i> , <b>2001</b> , 166, 1391-1392	2.5	2
13	The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. <i>Journal of Urology</i> , <b>2019</b> , 201, 742-750	2.5	2
12	Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. <i>Current Urology Reports</i> , <b>2017</b> , 18, 48	2.9	1
11	Prostate cancer: The applicability of textural analysis of MRI for grading. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 185-6	5.5	1
10	Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 363.e13-363.e20	2.8	1

9	Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3926-9	2.2	1
8	Identification and preservation of accessory pudendal vessels during robot-assisted laparoscopic radical retropubic prostatectomy. <i>Journal of Robotic Surgery</i> , <b>2008</b> , 2, 31-4	2.9	1
7	Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. <i>American Journal of Clinical and Experimental Urology</i> , <b>2019</b> , 7, 215-222	1.6	1
6	Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network. <i>Journal of Medical Imaging</i> , <b>2020</b> , 7, 057501	2.6	0
5	Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. <i>BMC Urology</i> , <b>2019</b> , 19, 26	2.2	
4	New Perspectives in Prostate Cancer Belldegrun A., Kirby R.S. and Oliver R.T.D.: New Perspectives in Prostate Cancer. Oxford: Isis Medical Media, Ltd. 1998. 423 pages.. <i>Journal of Urology</i> , <b>1999</b> , 161, 1424-1425	2.5	
3	Trends in epidural anesthesia use at the time of radical cystectomy and its association with perioperative and survival outcomes: a population-based analysis. <i>American Journal of Clinical and Experimental Urology</i> , <b>2020</b> , 8, 28-37	1.6	
2	Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 247-254	8.7	
1	Epigenetic field alterations in non-tumor prostate tissues detect prostate cancer in urine.. <i>American Journal of Clinical and Experimental Urology</i> , <b>2021</b> , 9, 479-488	1.6	